Editorial Material
Multidisciplinary Sciences
Zak Doric, Ken Nakamura
Summary: By disrupting mitochondria in vulnerable neuronal cells, mice provide a new model of Parkinson's disease that challenges long-held ideas about the disease's motor symptoms.
Review
Geriatrics & Gerontology
Yu Li, Yuanyuan Chen, Lili Jiang, Jingyu Zhang, Xuhui Tong, Dapeng Chen, Weidong Le
Summary: Parkinson's disease, as the second most common neurodegenerative disease, is significantly influenced by intestinal inflammation and alpha-synuclein. Research suggests that intestinal inflammation and dysbiosis may be related to the occurrence and development of PD.
Review
Biochemistry & Molecular Biology
Lei Xiong, Jin-Xiu Pan, Hao-han Guo, Lin Mei, Wen-Cheng Xiong
Summary: Patients with Parkinson's disease exhibit systemic deficits, including arthritis and osteoporosis-like symptoms. Understanding the relationship between peripheral tissue deficits and brain pathology in PD development is still at an early stage, highlighting the complex interaction of genetic and environmental risk factors. Genetic mutations in various genes have been identified in PD patients, some of which are involved in regulation of bone metabolism, indicating potential links between PD risk genes and bone health.
CELL AND BIOSCIENCE
(2021)
Article
Clinical Neurology
Michael Lawton, Manuela M. X. Tan, Yoav Ben-Shlomo, Fahd Baig, Thomas Barber, Johannes C. Klein, Samuel G. Evetts, Stephanie Millin, Naveed Malek, Katherine Grosset, Roger A. Barker, Nigel Williams, David J. Burn, Thomas Foltynie, Huw R. Morris, Nicholas Wood, Donald G. Grosset, Michele Tao-Ming Hu
Summary: This study explores the genetics of four previously described subtypes of Parkinson's disease and finds associations between different subtypes and GBA gene mutations and genetic risk. These findings provide insights into the underlying disease mechanisms and pathogenesis in different subtypes of Parkinson's disease.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Neurosciences
Dong-Woo Ryu, Sang-Won Yoo, Yoon-Sang Oh, Kwang-Soo Lee, Seunggyun Ha, Joong- Seok Kim
Summary: According to this study, Parkinson's disease patients can be categorized into brain-predominant PD and PD with body involvement phenotypes based on the onset of cardiac sympathetic denervation (CSD). The study found that PD patients with body involvement had more severe initial symptoms and experienced faster progression of motor deterioration, indicating potentially more severe involvement of the central and peripheral nervous systems.
NEUROBIOLOGY OF DISEASE
(2022)
Review
Biochemistry & Molecular Biology
Sri Jayanti, Rita Moretti, Claudio Tiribelli, Silvia Gazzin
Summary: With the increase in life expectancy, the prevalence of Parkinson's disease is expected to rise, but the diagnosis still relies on clinical symptoms. Current treatments mainly focus on alleviating symptoms without stopping or slowing down disease progression. Therefore, exploring the therapeutic potential of bilirubin in PD is crucial for the development of disease-modifying treatments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Jay S. S. Schneider
Summary: Parkinson's disease is a progressive neurodegenerative disorder impacting millions of patients worldwide. While there are treatments available for symptoms, there is no proven therapy to slow or halt disease progression. The failure of disease-modifying agents in clinical trials can be attributed to factors such as patient selection and trial design. Additionally, treatment choices have not adequately addressed the multiple and complex pathogenic mechanisms involved in Parkinson's disease. This paper suggests that using multi-functional therapeutics, such as GM1 ganglioside, which target multiple pathogenic mechanisms, may be a promising alternative strategy for success.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Clinical Neurology
Kaitlyn M. L. Cramb, Dayne Beccano-Kelly, Stephanie J. Cragg, Richard Wade-Martins
Summary: Cramb et al. provide a review of evidence suggesting dopamine release deficits occur prior to neurodegeneration in Parkinson's disease. They also highlight the need for further investigation in understanding the mechanisms behind these deficits.
Article
Chemistry, Multidisciplinary
Eleanor Sinclair, Caitlin Walton-Doyle, Depanjan Sarkar, Katherine A. Hollywood, Joy Milne, Sze Hway Lim, Tilo Kunath, Anouk M. Rijs, Rob M. A. de Bie, Monty Silverdale, Drupad K. Trivedi, Perdita Barran
Summary: Parkinson's disease is a neurodegenerative disorder without a robust clinical diagnostic test. Skin disorders and a characteristic odor from the skin of PD patients have been associated with the disease. Analysis of volatile components from sebum showed a differential profile between PD and control cohorts.
ACS CENTRAL SCIENCE
(2021)
Review
Pharmacology & Pharmacy
Mahalaxmi Iyer, Mohana Devi Subramaniam, Dhivya Venkatesan, Ssang-Goo Cho, Matias Ryding, Morten Meyer, Balachandar Vellingiri
Summary: Parkinson's disease is a complex neurodegenerative disease characterized by depletion of midbrain dopaminergic neurons. Current challenges in PD research include finding therapies to stop or reverse disease progression, identifying reliable biomarkers, and improving understanding of the pathophysiological mechanisms. The RhoA-ROCK signaling pathway shows promise in potentially addressing PD symptoms and pathogenesis.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Food Science & Technology
Yujie Chen, Wuke Yuan, Qi Xu, Manju B. Reddy
Summary: Parkinson's disease (PD) and Alzheimer's disease (AD) are common neurodegenerative disorders with shared molecular mechanisms, and there is currently no effective treatment. However, research suggests that consuming phytochemicals may help delay the progression of these diseases.
JOURNAL OF FUNCTIONAL FOODS
(2023)
Review
Biochemistry & Molecular Biology
Karim E. Shalaby, Omar M. A. El-Agnaf
Summary: Gene therapy has the potential to replace current treatments for Parkinson's disease and has been shown to be safe and effective in current trials.
Review
Biochemistry & Molecular Biology
Elena Piccinin, Anna Maria Sardanelli, Peter Seibel, Antonio Moschetta, Tiziana Cocco, Gaetano Villani
Summary: Parkinson's disease is characterized by the progressive loss of dopaminergic neurons, with mitochondrial dysfunction considered central to its pathogenesis. Failure of mitochondrial quality control is a hallmark of the disease, with the PGC-1 family playing a crucial role in regulating mitochondrial biogenesis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biotechnology & Applied Microbiology
Amanda Li, Joel Tyson, Shivni Patel, Meer Patel, Sruthi Katakam, Xiaobo Mao, Weiwei He
Summary: With the aging population, the prevalence of neurodegenerative diseases such as PD and AD is expected to rise. These diseases are classified as proteinopathies with misfolded proteins like alpha-synuclein, amyloid-beta, and tau. Nanomaterials offer advantages over traditional therapies in targeting specific mechanisms, such as reducing oxidative stress or disaggregating fibrils.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
Article
Clinical Neurology
Thomas Payne, Toby Burgess, Stephen Bradley, Sarah Roscoe, Matilde Sassani, Mark J. Dunning, Dena Hernandez, Sonja Scholz, Alisdair McNeill, Rosie Taylor, Li Su, Iain Wilkinson, Thomas Jenkins, Heather Mortiboys, Oliver Bandmann
Summary: This study characterized bioenergetic dysfunction in Parkinson's disease using a multimodal approach, and found impaired mitophagy and mitochondrial uncoupling in patient-derived fibroblasts. The study also revealed abnormal phosphocreatine levels and implicated a link between impaired mitophagy and impaired striatal energy homeostasis in early Parkinson's disease.
